People · Operator

MATTHEW SWANSON

Named in public records as an officer, director or promoter · active 2016–2025 · Healthtech, Other, Consumer / Retail

3
Companies
6
Filings
$27.7M
Combined raised · real
Serial
Operator type
Companies
CompanyRoleSectorStageRaised · realValue · estTied
Reema Health Inc.HealthtechSeries B$18.9M$93.1M2025
Augment Solutions, Inc.OtherSeries A$4.9M$74.1M2017
Rethink Brands, Inc.Consumer / RetailSeed$3.9M$8.2M2016
Operator network

MATTHEW SWANSON at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.

Helen Ciesielski · 3 companies · 1 sharedHelen CiesielskiMike Cunningham · 3 companies · 1 sharedMike CunninghamEllen Herlacher · 2 companies · 1 sharedEllen HerlacherAmon Anderson · 1 companies · 1 sharedAmon AndersonJustin Ley · 1 companies · 1 sharedJustin LeyMichael Dean · 3 companies · 1 sharedMichael DeanChristopher Konieczny · 2 companies · 1 sharedChristopher Konie…CHRIS O'DONOVAN · 1 companies · 1 sharedCHRIS O'DONOVANDANIEL BAUMWALD · 1 companies · 1 sharedDANIEL BAUMWALDMichael Lerner · 1 companies · 1 sharedMichael LernerTodd Fletcher · 1 companies · 1 sharedTodd FletcherReema Health Inc. · $18.9M raisedReema Health Inc.Augment Solutions, Inc. · $4.9M raisedAugment Solutions, In…Rethink Brands, Inc. · $3.9M raisedRethink Brands, Inc.MATTHEW SWANSONMS
MATTHEW SWANSON Company Co-operator (ring = serial)Hover to isolate ties · click to open
Co-operators (shared boards)

People named alongside MATTHEW SWANSON on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.

OperatorSharedTheir companies
Michael Dean13
Helen Ciesielski13
Mike Cunningham13
Ellen Herlacher12
Christopher Konieczny12
CHRIS O'DONOVAN11
Todd Fletcher11
DANIEL BAUMWALD11
Amon Anderson11
Justin Ley11
Michael Lerner11

People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.